Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.
Investors can access presentation materials and slides on the company's investor relations events page at the time of posting.
Positive
- None.
Negative
- None.
News Market Reaction – DNA
On the day this news was published, DNA gained 0.63%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ANAB up 10.08%, XNCR up 2.02%, while MGTX, KROS, and SEPN are down between 1.15% and 2.39%, suggesting DNA’s move is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 22 | ARPA-H partnership | Positive | +8.5% | ARPA-H backed POSEIDON oncology screening partnership with Carnegie Mellon. |
| Dec 17 | Manufacturing collaboration | Positive | -0.2% | Collaboration with Agricen to optimize fermentation for soil amendment product. |
| Dec 09 | Drug safety platform | Positive | +1.7% | ARPA-H funded PREDICTS drug safety data platform with Deep Origin. |
| Dec 05 | DOE phenotyping contract | Positive | +0.4% | Four-year, up to $47M contract for high-throughput phenotyping platform. |
| Dec 03 | ARPA-H EMBODY support | Positive | +4.9% | Participation in STRM.BIO’s ARPA-H EMBODY-funded MV gene therapy program. |
Recent partnership and contract announcements have more often led to positive 1-day price reactions, with one notable divergence.
Over the last months, Ginkgo Bioworks reported several partnership and contract wins. On Dec 22, 2025, an ARPA-H backed cancer screening partnership with Carnegie Mellon saw shares rise 8.52%. Earlier in December, collaborations with Agricen, Deep Origin, and PNNL, including a contract of up to $47M, produced modest moves between -0.24% and 1.70%. Participation in today’s J.P. Morgan Healthcare Conference fits a pattern of ongoing business development and visibility-building announcements.
Regulatory & Risk Context
The company has an active S-3 shelf registration filed on 2025-08-07, expiring on 2028-08-07, with 1 recorded usage via a 424B5 prospectus supplement dated 2025-09-04.
Market Pulse Summary
This announcement highlights Ginkgo Bioworks’ participation in the 44th Annual J.P. Morgan Healthcare Conference, with management presenting on January 15, 2026. It follows a series of ARPA-H backed collaborations and government contracts, including a deal of up to $47M, underscoring a focus on platform partnerships. Investors may watch for any new disclosures from the presentation and monitor subsequent regulatory filings, given the active S-3 shelf and prior 424B5 prospectus supplement.
AI-generated analysis. Not financial advice.
Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-the-44th-annual-jp-morgan-healthcare-conference-302659475.html
SOURCE Ginkgo Bioworks
FAQ
When will Ginkgo Bioworks (DNA) present at the J.P. Morgan Healthcare Conference?
Who from Ginkgo Bioworks (DNA) is presenting at the January 2026 J.P. Morgan conference?
Where can investors find Ginkgo Bioworks (DNA) presentation slides from the J.P. Morgan conference?
Will Ginkgo Bioworks (DNA) provide a webcast or replay for the January 15, 2026 presentation?
How should shareholders follow Ginkgo Bioworks (DNA) updates from the J.P. Morgan Healthcare Conference?
